Susquehanna International Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-40,000
| Closed | -$2.35M | – | 13832 |
|
|
2023
Q4 | $2.35M | Sell |
40,000
-65,300
| -62% | -$3.67M | ﹤0.01% | 5028 |
|
|
2023
Q3 | $4.59M | Buy |
105,300
+49,900
| +90% | +$1.78M | ﹤0.01% | 3682 |
|
|
2023
Q2 | $2M | Buy |
55,400
+16,300
| +42% | +$672K | ﹤0.01% | 5160 |
|
|
2023
Q1 | $1.45M | Sell |
39,100
-46,200
| -54% | -$2.08M | ﹤0.01% | 5878 |
|
|
2022
Q4 | $3.86M | Sell |
85,300
-42,500
| -33% | -$2.75M | ﹤0.01% | 3626 |
|
|
2022
Q3 | $8.93M | Buy |
127,800
+4,300
| +3% | +$318K | ﹤0.01% | 2317 |
|
|
2022
Q2 | $8.29M | Buy |
123,500
+99,800
| +421% | +$6.35M | ﹤0.01% | 2458 |
|
|
2022
Q1 | $1.95M | Sell |
23,700
-70,300
| -75% | -$7.19M | ﹤0.01% | 5538 |
|
|
2021
Q4 | $13.8M | Sell |
94,000
-29,400
| -24% | -$4.56M | ﹤0.01% | 2285 |
|
|
2021
Q3 | $21.8M | Buy |
123,400
+78,100
| +172% | +$12.6M | ﹤0.01% | 1884 |
|
|
2021
Q2 | $7.32M | Buy |
45,300
+600
| +1% | +$96.3K | ﹤0.01% | 3368 |
|
|
2021
Q1 | $7.66M | Sell |
44,700
-150,700
| -77% | -$29.8M | ﹤0.01% | 3206 |
|
|
2020
Q4 | $42.9M | Buy |
195,400
+95,900
| +96% | +$20.7M | 0.01% | 1102 |
|
|
2020
Q3 | $16.5M | Buy |
99,500
+17,400
| +21% | +$2.38M | ﹤0.01% | 1673 |
|
|
2020
Q2 | $9.37M | Sell |
82,100
-151,800
| -65% | -$14.7M | ﹤0.01% | 2210 |
|
|
2020
Q1 | $18M | Buy |
233,900
+15,200
| +7% | +$1.36M | 0.01% | 1249 |
|
|
2019
Q4 | $28.2M | Sell |
218,700
-456,500
| -68% | -$44M | 0.01% | 1156 |
|
|
2019
Q3 | $52.6M | Buy |
675,200
+263,700
| +64% | +$24.7M | 0.02% | 708 |
|
|
2019
Q2 | $42.4M | Buy |
411,500
+322,000
| +360% | +$25.1M | 0.02% | 786 |
|
|
2019
Q1 | $6.56M | Buy |
89,500
+44,300
| +98% | +$3.01M | ﹤0.01% | 2152 |
|
|
2018
Q4 | $1.92M | Sell |
45,200
-137,300
| -75% | -$5.47M | ﹤0.01% | 3589 |
|
|
2018
Q3 | $8.6M | Buy |
182,500
+97,100
| +114% | +$5.41M | ﹤0.01% | 2093 |
|
|
2018
Q2 | $4.21M | Buy |
85,400
+47,400
| +125% | +$1.79M | ﹤0.01% | 2938 |
|
|
2018
Q1 | $1.17M | Sell |
38,000
-46,200
| -55% | -$1.28M | ﹤0.01% | 4935 |
|
|
2017
Q4 | $1.54M | Buy |
84,200
+50,100
| +147% | +$777K | ﹤0.01% | 4412 |
|
|
2017
Q3 | $399K | Buy |
+34,100
| New | +$197K | ﹤0.01% | 6926 |
|
|
2015
Q4 | – | Sell |
-71,800
| Closed | -$2.47M | – | 10113 |
|
|
2015
Q3 | $2.47M | Buy |
71,800
+57,600
| +406% | +$1.74M | ﹤0.01% | 3877 |
|
|
2015
Q2 | $447K | Buy |
+14,200
| New | +$418K | ﹤0.01% | 7845 |
|
Other funds holding MRTX
Susquehanna International Group's MRTX Position: Q1 2024 in Review
Susquehanna International Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 145,890 shares — an estimated $8.57M sold.
Susquehanna International Group first reported a position in MRTX in Q2 2015 and held it in 29 quarters. The position peaked at $15.7M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Susquehanna International Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Susquehanna International Group sold 145,890 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $8.57M.
- Susquehanna International Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 29 quarters.
- Susquehanna International Group's Mirati Therapeutics, Inc. Common Stock position peaked at $15.7M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.